Denver, CO (PRWEB) December 06, 2012
The DrugRisk Resource Center is alerting patients taking the blood thinner Pradaxa that health experts continue to disagree about the safety of the drug and its propensity to cause dangerous or fatal internal bleeding.
Last month, the FDA updated its warnings to say that, for now, testing shows Pradaxa carries the same risks as warfarin and Coumadin.* However, the New York Times published a story the same day detailing concerns of doctors that Pradaxa led all other medications for adverse reports and currently has no antidote for internal bleeding.**
Amidst the dispute, the number of Pradaxa lawsuits filed has risen by 50% since September, according to the November 14, 2012 report of the Judicial Panel on MultiDistrict Litigation.***
Anyone affected by internal bleeding after taking Pradaxa is urged to speak with a lawyer about their legal options as soon as possible.
Due to the growing number of Pradaxa lawsuits, cases have been moved to a special federal court in Illinois. The formal case is known as MDL No. 2385, IN RE: Pradaxa Product Liability Litigation, Southern District of Illinois.
U.S. District Judge David Herndon, who presides over the nationwide Pradaxa lawsuits, recently ordered that manufacturer Boehringer Ingelheim will have until December 17th to produce evidence disputing claims that the drug can cause dangerous or fatal bleeding.****
Anyone affected by internal bleeding after Pradaxa use is urged to speak with a lawyer about their legal options as soon as possible. Due to the specialized nature of federal drug injury cases, the Drug Risk Resource Center only recommends lawyers who are already handling Pradaxa lawsuits.
For more information on the research, side effects and litigation news related to Pradaxa and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.